

## Lao PDR Support for Inactivated Polio Vaccine (IPV)

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Lao PDR			
<b>2. Grant number:</b> 1518-LAO-25b-X /			
<b>3. Date of Decision Letter:</b> 15 February 2017			
<b>4. Date of the Partnership Framework Agreement:</b> June 7, 2013			
<b>5. Programme title:</b> NVS, IPV routine			
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)			
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>2</sup>:</b> 2015- 2018			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2016	2017	Total <sup>3</sup>
Programme Budget (US\$)	571,351	329,000	900,351
<b>10. Vaccine introduction grant:</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2017		
Number of IPV vaccines doses	168,100		
Annual Amounts (US\$)	329,000		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2017.

<sup>4</sup> This is the amount that Gavi has approved.

<p><b>14. Co-financing obligations:</b> Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Lao PDR is encouraged to contribute to vaccine and/or supply costs for IPV.</p>							
<p><b>15. Operational support for campaigns:</b> Not applicable</p>							
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat						
<p><b>17. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*: <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>							
<p><b>18. Other conditions:</b></p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the presentation and actual number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>							

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
15 February 2017